Evidence Hub

Testosterone Replacement Therapy

Giulia Rastrelli, Yacov Reisman, Simona Ferri, Olga Prontera, Alessandra Sforza, Mario Maggi, Giovanni Corona

Sexual Medicine, 2018

3 citations

Abstract

Male hypogonadism (HG) can be defined according to its etiology as primary (pHG) when caused by any diseases affecting the testes, or as secondary (sHG) when due to a pituitary or hypothalamic dysfunction. Both fertility and testosterone (T) can be theoretically restored in sHG by removing the precipitating cause and/or by appropriate endocrine therapy. Conversely, only T treatment can be offered to patients with pHG. Symptoms and signs are quite similar independent of the underlying causes. Conversely, the phenotype of the hypogonadal patient is more often affected by the age of hypogonadism onset. Late-onset hypogonadism (LOH) that occurs in adulthood is probably the most common form of HG. In this chapter, the criteria defining LOH and the available T formulations along with their outcomes and main important side effects are analyzed in detail. Testosterone replacement therapy (TRT) can be administered with different modalities including oral, transdermal, and injectable formulations. The available meta-analyses show that TRT is able to improve sexual function and body composition whereas the data on the risk of bone fractures, mood, and cognition are more conflicting. Available evidence indicates that cardiovascular (CV) and venous thromboembolism risk are not major issues and that prostate safety is guaranteed when TRT is prescribed according to current guidelines. The risk of increased hematocrit is mainly limited to the use of short-term injectable preparations. These…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free